Letter

Van Rompay K.K.A. (2017). Tackling HIV and AIDS: Contributions by non-human primate models. Lab Animal 46, 259–270.

Bailey J. (2008). An assessment of the role of chimpanzees in AIDS vaccine research. ATLA 36, 381–428.

Pitisuttithum P. , Gilbert P. , Gurwith M. , Heyward W. , Martin M. , van Griensven F. , Hu D. , Tappero J.W. , & Choopanya K ; Bangkok Vaccine Evaluation Group (2006). Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. Journal of Infectious Diseases 194, 1661–1671.

Altman L.K. , & Pollack A. (2007). Failure of vaccine test is setback in AIDS fight. New York Times, 22 September 2017. Available at: http://www.nytimes.com/2007/09/22/health/22vaccine.html (Accessed 19.09.17).

Merck & Co., Inc., (2007). Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate. Interim Analysis of STEP Study Shows Vaccine was Not Effective. Available at: http://www.thebodypro.com/content/art43269.html (Accessed 19.09.17).

Cohen J. (2007). AIDS research. Did Merck's failed HIV vaccine cause harm? Science, New York, 318, 1048–1049.

Gray G.E. , Allen M. , Moodie Z. , Churchyard G. , Bekker L.G. , Nchabeleng M. , Mlisana K. , Metch B. , de Bruyn G. , Latka M.H. , Roux S. , Mathebula M. , Naicker N. , Ducar C. , Carter D.K. , Puren A. , Eaton N. , McElrath M.J. , Robertson M. , Corey L. , & Kublin J.G. ; HVTN 503/Phambili study team (2011). Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of- concept phase 2b study. Lancet Infectious Diseases 11, 507–515.

Rerks-Ngarm S. , Pitisuttithum P. , Nitayaphan S. , Kaewkungwal J. , Chiu J. , Paris R. , Premsri N. , Namwat C. , de Souza M. , Adams E. , Benenson M. , Gurunathan S. , Tartaglia J. , McNeil J.G. , Francis D.P. , Stablein D. , Birx D.L. , Chunsuttiwat S. , Kham boonruang C. , Thongcharoen P. , Robb M.L. , Michael N.L. , Kunasol P. , & Kim J.H. ; MOPHTAVEG investigators (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New England Journal of Medicine 361, 2209–2220.

da Silva L.J. , & Richtmann R. (2006). Vaccines under development: Group B streptococcus, herpes-zoster, HIV, malaria and dengue. Jornal de Pediatria 82, S115–S124.

Tonks A. (2007). Quest for the AIDS vaccine. BMJ 334, 1346–1348.

D'Souza M.P. , Allen M. , Sheets R. , & Johnston M.I. (2004). Current advances in HIV vaccines. Current HIV/AIDS Reports 1, 18–24.

Johnston M.I. (2000). The role of nonhuman primate models in AIDS vaccine development. Molecular Medicine Today 6, 267–270.

Hu S.L. (2005). Non-human primate models for AIDS vaccine research. Current Drug Targets Infectious Disorders 5, 193–201.

Levy Y. (2005). Therapeutic HIV vaccines: An update. Current HIV/AIDS Reports 2, 5–9.

Tonini T. , Barnett S. , Donnelly J. , & Rappuoli R. (2005). Current approaches to developing a preventative HIV vaccine. Current Opinion in Investigational Drugs 6, 155–162.

Wyand M.S. (1992). The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines. AIDS Research & Human Retroviruses 8, 349–356.

Desrosiers R.C. , & Bolognesi D.P. (1994). Controversies in science: A live-virus AIDS vaccine? Journal of NIH Research, 6, 54–54.

Grant B. (2009). HIV vax testers react to Thai trial. The Scientist, 24 September 2009. Available at: http://www.the-scientist.com/?articles.view/articleNo/27669/title/HIV-vax-testers-react-to-Thai-trial/ (Accessed 19.09.17).

Humes D. , Emery S. , Laws E. , & Overbaugh J. (2012). A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection. Journal of Virology 86, 12,472–12,483.

Fauci A.S. (2008). 25 years of HIV. Nature, London 453, 289–290.

Haynes B.F. , & Burton D.R. (2017). Developing an HIV vaccine. Science, New York 355, 1129–1130.

International Conference on Harmonisation (2005). Guideline: Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility S5(R2), 24 pp. Geneva, Switzerland: ICH. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S5/Step4/S5_R2__Guideline.pdf (Accessed 19.09.17).

Bailey J. (2008). Developmental toxicity testing: protecting future generations? ATLA, 36, 718–721.

Matthews R.A. (2008). Medical progress depends on animal models — doesn't it? Journal of the Royal Society of Medicine, 101, 95–98.

Spanhaak S. , Cook D. , Barnes J. , & Reynolds J. (2008). Species Concordance for Liver Injury, 6 pp. Cambridge, UK: Biowisdom Ltd.

Robinson S. , Delongeas J.L. , Donald E. , Dreher D. , Festag M. , Kervyn S. , Lampo A. , Nahas K. , Nogues V. , Ockert D. , Quinn K. , Old S. , Pickersgill N. , Somers K. , Stark C. , Stei P. , Waterson L. , & Chapman K. (2008). A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regulatory Toxicology & Pharmacology 50, 345–352.

Bailey J. , Thew M. , & Balls M. (2015). Predicting human drug toxicity and safety via animal tests: Can any one species predict drug toxicity in any other, and do monkeys help? ATLA, 43, 393–403.

Bailey J. (2011). Lessons from chimpanzee-based research on human disease: The implications of genetic differences. ATLA 39, 527–540.

Bailey J. (2014). Monkey-based research on human disease: The implications of genetic differences. ATLA 42, 287–317.

Trichel A.M. , Rajakumar P.A. , & Murphey-Corb M. (2002). Species-specific variation in SIV disease progression between Chinese and Indian subspecies of rhesus macaque. Journal of Medical Primatology 31, 171–178.

Laguette N. , Sobhian B. , Casartelli N. , Ringeard M. , Chable-Bessia C. , Ségéral E. , Yatim A. , Emiliani S. , Schwartz O. , & Benkirane M. (2011). SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature, London 474, 654–657.

Hrecka K. , Hao C. , Gierszewska M. , Swanson S.K. , Kesik-Brodacka M. , Srivastava S. , Florens L. , Washburn M.P. , & Skowronski J. (2011). Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature, London 474, 658–661.

Hatziioannou T. , & Evans D.T. (2012). Animal models for HIV/AIDS research. Nature Reviews Microbiology 10, 852–867.

VandeBerg J.L. , & Zola S.M. (2005). A unique biomedical resource at risk. Nature, London 437, 30–32.

Fauci A.S. , & Fischinger P.J. (1988). The development of an AIDS vaccine: Progress and promise. Public Health Reports 103, 230–236.

Institute of Medicine (2011). Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity, 190 pp. Washington, DC, USA: The National Academies Press.

Ipsos MORI (2014). Attitudes to Animal Research in 2014 — A Report by Ipsos MORI for the Department for Business, Innovation & Skills, 53 pp. London, UK: Ipsos MORI. Available at: https://www.ipsos-mori.com/researchpublications/publications/1695/Attitudes-to-animal-research-in-2014.aspx (Accessed 19.09.17).

BUAV/YouGov plc (2009). Opinion poll on animal experiments, Sample Size: 7139, Fieldwork: 24 February 2009–4 March 2009. London, UK: BUAV. [Available on request.]

TNS Opinion, & Social network (2010). Special Eurobarometer 340/ Wave 73.1, Science and Technology Report, 61, 163 pp. Brussels, Belgium: European Commission. Available at: http://ec.europa.eu/public_opinion/archives/ebs/ebs_340_en.pdf (Accessed 19.09.17).

Neff E.P. (2017). Recapping the NIH workshop on NHPs. Lab Animal 46, 6, 233–234.

Cockerham L.R. , Hatano H. , & Deeks S.G. (2016). Post-treatment controllers: Role in HIV “cure” research. Current HIV/AIDS Reports 13, 1–9.

Katlama C. , Deeks S.G. , Autran B. , Martinez-Picado J. , van Lunzen J. , Rouzioux C. , Miller M. , Vella S. , Schmitz J.E. , Ahlers J. , Richman D.D. , & Sekaly R.P. (2013). Barriers to a cure for HIV: New ways to target and eradicate HIV-1 reservoirs. Lancet 381, 2109–2117.

Jacobs E.S. , Keating S.M. , Abdel-Mohsen M. , Gibb S.L. , Heitman J.W. , Inglis H.C. , Martin J.N. , Zhang J. , Kaidarova Z. , Deng X. , Wu S. , Anastos K. , Crystal H. , Villacres M.C. , Young M. , Greenblatt R.M. , Landay A.L. , Gange S.J. , Deeks S.G. , Golub E.T. , Pillai S.K. , & Norris P.J. (2017). Cytokines elevated in HIV elite controllers reduce HIV replication in vitro and modulate HIV restriction factor expression. Journal of Virology 91 [doi: 10.1128/JVI.02051-16].

Matsuzawa T. , Ogawa Y. , Moriishi K. , Shimada S. , & Kawamura T. (2017). Immunological function of Langerhans cells in HIV infection. Journal of Dermatological Science 87, 159–167.

Petrovas C. , Ferrando-Martinez S. , Gerner M.Y. , Casazza J.P. , Pegu A. , Deleage C. , Cooper A. , Hataye J. , Andrews S. , Ambrozak D. , Del Río Estrada P.M. , Boritz E. , Paris R. , Moysi E. , Boswell K.L. , Ruiz-Mateos E. , Vagios I. , Leal M. , Ablanedo-Terrazas Y. , Rivero A. , Gonzalez-Hernandez L.A. , McDermott A.B. , Moir S. , Reyes-Terán G. , Docobo F. , Pantaleo G. , Douek D.C. , Betts M.R. , Estes J.D. , Germain R.N. , Mascola J.R. , & Koup R.A. (2017). Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Science Translational Medicine 9 [doi: 10.1126/scitranslmed.aag2285].

He X. , Simoneau C.R. , Granoff M.E. , Lunemann S. , Dugast A.S. , Shao Y. , Altfeld M. , & Körner C. (2016). Assessment of the antiviral capacity of primary natural killer cells by optimized in vitro quantification of HIV-1 replication. Journal of Immuno logical Methods 434, 53–60.

Curreli F. , Kwon Y.D. , Belov D.S. , Ramesh R.R. , Kurkin A.V. , Altieri A. , Kwong P.D. , & Debnath A.K. (2017). Synthesis, antiviral potency, in vitro ADMET, and X-ray structure of potent CD4 mimics as entry inhibitors that target the Phe43 cavity of HIV-1 gp120. Journal of Medicinal Chemistry 60, 3124–3153.

Malik T. , Chauhan G. , Rath G. , Murthy R.S. , & Goyal A.K. (2017). “Fusion and binding inhibition” key target for HIV-1 treatment and pre-exposure prophylaxis: Targets, drug delivery and nanotechnology approaches. Drug Delivery 24, 608–621.

Jagarapu A. , Cannon L.M. , & Zurakowski R. (2017). Experiment design for early molecular events in HIV infection. In 2017 American Control Conference (ACC), pp. 122–127. Available at: http://ieeexplore.ieee.org/document/7962941/ (Accessed 19.09.17).

Nemeth J. , Vongrad V. , Metzner K.J. , Strouvelle V.P. , Weber R. , Pedrioli P. , Aebersold R. , Günthard H.F. , & Collins B.C. (2017). In vivo and in vitro proteome analysis of human immunodeficiency virus (HIV)-1-infected, human CD4⁺ T cells. Molecular & Cellular Proteomics 16, S108–S123.

González M.E. (2017). The HIV-1 Vpr protein: A multifaceted target for therapeutic intervention. International Journal of Molecular Sciences 18 [doi: 10.3390/ijms18010126].

Gray E.R. , Brookes J.C. , Caillat C. , Turbé V. , Webb B.L.J. , Granger L.A. , Miller B.S. , McCoy L.E. , El Khattabi M. , Verrips C.T. , Weiss R.A. , Duffy D.M. , Weissenhorn W. , & McKendry R.A. (2017). Unravelling the molecular basis of high affinity nanobodies against HIV p24: In vitro functional, structural, and in silico insights. ACS Infectious Diseases 3, 479–491.

Liu L. , Wang W. , Matz J. , Ye C. , Bracq L. , Delon J. , Kimata J.T. , Chen Z. , Benichou S. , & Zhou P. (2016). The glycosylphosphatidylinositol-anchored variable region of llama heavy chain-only antibody JM4 efficiently blocks both cell-free and T cell–T cell transmission of human immunodeficiency virus type 1. Journal of Virology 90, 10,642–10,659.

Cunha-Santos C. , Figueira T.N. , Borrego P. , Oliveira S.S. , Rocha C. , Couto A. , Cantante C. , Santos-Costa Q. , Azevedo-Pereira J.M. , Fontes C.M. , Taveira N. , Aires-Da-Silva F. , Castanho M.A. , Veiga A.S. , & Goncalves J. (2016). Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors. AIDS 30, 1691–1701.

Romao E. , Morales-Yanez F. , Hu Y. , Crauwels M. , De Pauw P. , Hassanzadeh G.G. , Devoogdt N. , Ackaert C. , Vincke C. , & Muyldermans S. (2016). Identification of useful nanobodies by phage display of immune single domain libraries derived from camelid heavy chain antibodies. Current Pharmaceutical Design 22, 6500–6518.

Vanlandschoot P. , Stortelers C. , Beirnaert E. , Ibañez L.I. , Schepens B. , Depla E. , & Saelens X. (2011). Nanobodies^®: New ammunition to battle viruses. Antiviral Research 92, 389–407.